Zetia: Targeted Cholesterol Management for Lower LDL
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.46 | $43.86 (0%) | 🛒 Add to cart |
| 60 | $1.18 | $87.72 $70.52 (20%) | 🛒 Add to cart |
| 90 | $1.08 | $131.58 $97.18 (26%) | 🛒 Add to cart |
| 120 | $1.04 | $175.44 $124.70 (29%) | 🛒 Add to cart |
| 180 | $0.99 | $263.16 $178.02 (32%) | 🛒 Add to cart |
| 270 | $0.96 | $394.74 $258.86 (34%) | 🛒 Add to cart |
| 360 | $0.94
Best per pill | $526.32 $338.84 (36%) | 🛒 Add to cart |
Synonyms | |||
Zetia (ezetimibe) represents a significant advancement in the management of high cholesterol, offering a targeted mechanism of action distinct from statins. As a selective cholesterol absorption inhibitor, it works directly in the digestive system to reduce the amount of cholesterol the body absorbs from food. This monograph provides a comprehensive, expert-level overview of Zetia, detailing its pharmacology, clinical applications, and practical considerations for healthcare professionals and informed patients. It is designed to be used as an authoritative reference alongside, not in place of, direct medical guidance from a qualified physician.
Features
- Active Ingredient: Ezetimibe
- Drug Class: Selective Cholesterol Absorption Inhibitor
- Standard Tablet Strength: 10 mg
- Administration: Oral tablet
- Mechanism: Acts at the brush border of the small intestine to inhibit the absorption of dietary and biliary cholesterol.
- Bioavailability: Not significantly affected by food intake.
- Primary Metabolic Pathway: Glucuronide conjugation in the small intestine and liver.
- Elimination: Primarily fecal (~78%), with minor renal excretion (~11%).
Benefits
- Lowers LDL-C Effectively: Provides a significant reduction in low-density lipoprotein cholesterol (LDL-C or “bad” cholesterol) as a monotherapy.
- Complementary Mechanism: Can be combined with statin therapy (e.g., as in Vytorin) for dual-action inhibition of both cholesterol production and absorption, leading to greater LDL-C reduction than either agent alone.
- Modestly Improves Other Lipid Parameters: Can lead to small decreases in triglycerides and a slight increase in high-density lipoprotein cholesterol (HDL-C or “good” cholesterol).
- Non-Systemic Action: Its primary site of action is localized to the intestine, which may be beneficial for patients who cannot tolerate systemically-acting therapies.
- Convenient Dosing: A simple, once-daily oral regimen supports long-term adherence to therapy.
- Established Cardiovascular Outcome Benefit: When added to statin therapy, it has been shown to reduce the risk of major atherosclerotic cardiovascular events in specific high-risk patient populations.
Common use
Zetia is indicated as an adjunct to diet for the reduction of elevated LDL-C in patients with primary hyperlipidemia, either as monotherapy or in combination with an HMG-CoA reductase inhibitor (statin). It is also used to reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia (phytosterolemia). It is commonly prescribed for patients who have not achieved their LDL-C goals with statin monotherapy, for those who are statin-intolerant, or as initial therapy in certain clinical scenarios where a statin may not be the first choice.
Dosage and direction
- The recommended dosage for Zetia is 10 mg taken once daily, with or without food.
- It can be taken at any time of the day, but taking it at a consistent time each day is advised to maintain steady drug levels.
- When co-administered with a bile acid sequestrant (e.g., cholestyramine), Zetia should be taken at least 2 hours before or at least 4 hours after the bile acid sequestrant.
- For pediatric patients (10 years of age and older), the dose is also 10 mg once daily.
- No dosage adjustment is necessary for geriatric patients or those with mild hepatic impairment or chronic renal disease.
Precautions
- Liver Enzymes: Liver function tests should be performed at initiation of therapy and according to clinical judgment thereafter. Rare cases of severe liver injury have been reported.
- Muscle Pain: Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise, though the risk of myopathy is lower with Zetia than with statins.
- Pregnancy and Lactation: Zetia should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not recommended for use in nursing mothers due to the potential for serious adverse reactions in nursing infants.
- Hepatic Impairment: Not recommended in patients with moderate to severe hepatic impairment.
- Underlying Causes: Therapy with a lipid-altering agent should be a component of multiple risk factor intervention in individuals at high risk for atherosclerotic vascular disease. It is not a substitute for addressing underlying causes of hyperlipidemia, such as poor diet, lack of exercise, or obesity.
Contraindications
Zetia is contraindicated in patients with a known hypersensitivity to any component of the medication. The combination of Zetia with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases.
Possible side effect
The most common side effects reported with Zetia monotherapy are generally mild and include:
- Diarrhea
- Upper respiratory tract infection
- Muscle spasms (less common than with statins)
- Sinusitis
- Arthralgia (joint pain)
- Pain in an extremity
- Fatigue
When used in combination with a statin, the side effect profile reflects the combined effects of both drugs. Rare but serious side effects can include:
- Rhabdomyolysis and myopathy (more common with combination therapy)
- Hepatitis, including severe liver injury
- Pancreatitis
- Allergic reactions, including angioedema and rash
- Depression
- Dizziness
Drug interaction
- Bile Acid Sequestrants (e.g., cholestyramine): Co-administration may significantly decrease the bioavailability of ezetimibe. Dosing should be separated as described in the “Dosage” section.
- Fibrates: Concurrent use may increase the risk of cholelithiasis and is generally not recommended unless the potential benefit outweighs the risk.
- Cyclosporine: Concomitant use increases ezetimibe concentrations. This combination should be avoided unless the benefits outweigh the risks, and the patient should be monitored for adverse effects.
- Warfarin: Small but statistically significant increases in International Normalized Ratio (INR) have been reported. INR should be monitored in patients taking coumarin anticoagulants.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. The patient should not take a double dose to make up for the missed one.
Overdose
There is limited experience with Zetia overdose. In clinical studies, administration of ezetimibe, 50 mg/day, to healthy volunteers for 14 days was generally well tolerated. In the event of an overdose, symptomatic and supportive measures should be taken. Due to the extensive protein binding of ezetimibe, hemodialysis is not expected to be effective.
Storage
Zetia tablets should be stored at room temperature, between 20°C to 25°C (68°F to 77°F), in their original container. The medication must be kept in a dry place and out of reach of children and pets. Do not use after the expiration date printed on the bottle.
Disclaimer
This information is for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The author and publisher are not responsible for any errors or omissions or for any consequences from the application of this information.
Reviews
- Clinical Perspective (Dr. A. Reynolds, Cardiologist): “Zetia fills an important niche in our lipid-lowering arsenal. Its unique intestinal mechanism provides a valuable tool for patients who are statin-intolerant or need additional LDL-C lowering on top of a maximally tolerated statin. The IMPROVE-IT trial data solidified its role in reducing cardiovascular events in post-ACS patients when combined with simvastatin.”
- Patient Experience (J.K., 58-year-old patient): “After experiencing significant muscle pain on two different statins, my doctor switched me to Zetia. My LDL came down by about 18%, and I’ve had zero side effects. It’s been a game-changer for me, allowing me to manage my cholesterol without the debilitating pain I had before.”
- Pharmacology Review (Journal of Clinical Lipidology): “Ezetimibe’s well-tolerated profile and complementary mechanism of action make it a rational choice for combination therapy. Its effect on cardiovascular outcomes, while more modest than high-intensity statins, provides an evidence-based option for high-risk patients who cannot achieve goals with statin monotherapy.”